Oscotec Inc.
Financials
Valuation Metrics
Oscotec Inc.'s Market Cap is ₩1.4T. At end of 2025 it was ₩1.7T. Ranked #263 of 2,421 in KR market (top 11%), #64 of 1,640 on KOSDAQ (top 4%), #27 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.40T KRW | KR#263/2,421 Sec#27/231 |
| Revenue | 144.18B KRW | KR#1,207/2,421 Sec#73/231 |
| Net Income | 100.43B KRW | KR#251/2,421 Sec#14/231 |
| Total Assets | 267.18B KRW | KR#1,109/2,421 Sec#78/231 |
| Net Assets | 224.12B KRW | KR#884/2,421 Sec#62/231 |
| Employees | 51 | KR#2,045/2,421 Sec#188/231 |
| Value | ||
| P/E | 13.96x | KR#1,008/2,421 Sec#58/231 |
| P/B | 6.26x | KR#2,288/2,421 Sec#197/231 |
| PEG | 0.00x | KR#46/2,421 Sec#2/231 |
| P/S | 9.72x | KR#2,276/2,421 Sec#164/231 |
| EV/EBITDA | 15.46x | KR#874/2,421 Sec#52/231 |
| Profitability | ||
| ROE | 44.81% | KR#17/2,421 Sec#2/231 |
| ROA | 37.59% | KR#7/2,421 Sec#1/231 |
| Op. Margin | 62.23% | KR#5/2,421 Sec#1/231 |
| Revenue Growth | 232.64% | KR#31/2,421 Sec#9/231 |
| Earnings Growth | 4629.08% | KR#15/2,421 Sec#2/231 |
| Financial Health | ||
| Debt Ratio | 19.21% | KR#350/2,421 Sec#47/231 |
| Total Debt | 17.51B KRW | KR#1,426/2,421 Sec#116/231 |
| Cash | 32.39B KRW | KR#962/2,421 Sec#64/231 |
| Current Ratio | 6.09x | KR#210/2,421 Sec#42/231 |
| Net Debt/EBITDA | -0.17x | KR#577/2,421 Sec#34/231 |
| Performance | ||
| 1Y Return | -11.58% | KR#1,007/2,421 Sec#66/231 |
| 1M Return | -3.81% | KR#1,685/2,421 Sec#133/231 |
| From 52W High | -44.47% | KR#1,133/2,421 Sec#86/231 |
| 1Y MDD | -54.84% | KR#1,210/2,421 Sec#100/231 |
| Trading | ||
| Volume | 109,369 shares | KR#742/2,421 Sec#68/231 |
| Trading Value | 4.03B KRW | KR#411/2,421 Sec#41/231 |
| Foreign Own. | 12.30% | KR#402/2,421 Sec#30/231 |
| Per Share | ||
| EPS | 2,625 KRW | KR#381/2,421 Sec#25/231 |
| BPS | 5,858 KRW | KR#1,376/2,421 Sec#97/231 |
Company Info
Oscotec, a new drug development biotechnology company established in 1998, specializes in synthetic new drug development, building a differentiated business model through the commercialization of its research products. Its targeted anticancer lung cancer treatment received approval as a first-line treatment from the Korean Ministry of Food and Drug Safety and the U.S. FDA. The company's autoimmune disease treatment has applied for additional clinical trials after completing global Phase 2a for ITP disease, while its next-generation anticancer drug received U.S. FDA Phase 1 Investigational New Drug (IND) approval, and its Alzheimer's disease treatment is undergoing Phase 1 clinical trials in the U.S. Oscotec is headquartered in Seongnam-si, Gyeonggi-do.